Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 16/20 | 0.60 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.60 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.45 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6841890 | 0.88 | PARP1 (0.52) | PARP1CHEK2PKN1PKN2 | |
| SCHEMBL6841926 | 0.86 | PARP1 (0.57) | PARP1CHEK2PKN1PKN2 | |
| SCHEMBL6836719 | 0.85 | PARP1 (0.51) | PARP1PLA2G2AALOX15PTGS2 | |
| SCHEMBL6842026 | 0.84 | PARP1 (0.62) | PARP1 | |
| SCHEMBL6841889 | 0.83 | PARP1 (0.60) | PARP1CHEK2PKN1PKN2 | |
| SCHEMBL6841127 | 0.83 | PARP1 (0.62) | PARP1CHEK2PKN1PKN2 | |
| SCHEMBL6841505 | 0.83 | PARP1 (0.52) | PARP1CHEK2PKN1PKN2 | |
| SCHEMBL8620143 | 0.82 | PARP1 (0.65) | PARP1PLA2G2AALOX15PTGS2CHEK2 | |
| SCHEMBL6843633 | 0.81 | PARP1 (0.51) | PARP1 | |
| SCHEMBL6842040 | 0.80 | PARP1 (0.49) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034078-A1 | Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase | AGOURON PHARMACEUTICALS, INC. | 2004-02-19 | — | — | US | disclosed |
| WO-2003106430-A1 | BENZIMIDAZOLE INHIBITORS OF POLY(ADP-RIBOSYL) POLYMERASE | PFIZER INC. (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034078-A1 | Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase | PARP1, PARP11, PARP2 | PARP1 1/4885PLA2G2A 3293/4885ALOX15 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.